Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/214024
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRades, Dirk-
dc.contributor.authorLomidze, Darejan-
dc.contributor.authorJankarashvili, Natalia-
dc.contributor.authorLopez Campos, Fernando-
dc.contributor.authorNavarro-martin, Arturo-
dc.contributor.authorSegedin, Barbara-
dc.contributor.authorGroselj, Blaz-
dc.contributor.authorStaackmann, Christian-
dc.contributor.authorKristiansen, Charlotte-
dc.contributor.authorDennis, Kristopher-
dc.contributor.authorSchild, Steven E.-
dc.contributor.authorCacicedo, Jon-
dc.date.accessioned2024-07-01T09:09:06Z-
dc.date.available2024-07-01T09:09:06Z-
dc.date.issued2024-03-14-
dc.identifier.urihttp://hdl.handle.net/2445/214024-
dc.description.abstractSimple Summary Patients with MESCC and favorable survival prognoses assigned to radiotherapy alone may benefit from increased doses. In a multi-center phase 2 trial, patients receiving 15 x 2.633 Gy or 18 x 2.333 Gy were evaluated and subsequently compared to a historical control group receiving 10 x 3.0 Gy. The phase 2 cohort, including 50 (of 62 planned) evaluable patients, showed promising results regarding 12-month local progression-free survival (LPFS), 12-month overall survival (OS), improvement of motor and sensory functions, post-radiotherapy ambulatory status, and relief of pain and distress. Radiotherapy with 15 x 2.633 Gy or 18 x 2.333 Gy was well tolerated and appeared more effective than 10 x 3.0 Gy with respect to LPFS and improvement of motor function.Abstract Patients with metastatic epidural spinal cord compression (MESCC) and favorable survival prognoses may benefit from radiation doses exceeding 10 x 3.0 Gy. In a multi-center phase 2 trial, patients receiving 15 x 2.633 Gy (41.6 Gy10) or 18 x 2.333 Gy (43.2 Gy10) were evaluated for local progression-free survival (LPFS), motor/sensory functions, ambulatory status, pain, distress, toxicity, and overall survival (OS). They were compared (propensity score-adjusted Cox regression) to a historical control group (n = 266) receiving 10 x 3.0 Gy (32.5 Gy10). In the phase 2 cohort, 50 (of 62 planned) patients were evaluated for LPFS. Twelve-month rates of LPFS and OS were 96.8% and 69.9%, respectively. Motor and sensory functions improved in 56% and 57.1% of patients, and 94.0% were ambulatory following radiotherapy. Pain and distress decreased in 84.4% and 78.0% of patients. Ten and two patients experienced grade 2 and 3 toxicities, respectively. Phase 2 patients showed significantly better LPFS than the control group (p = 0.039) and a trend for improved motor function (p = 0.057). Ambulatory and OS rates were not significantly different. Radiotherapy with 15 x 2.633 Gy or 18 x 2.333 Gy was well tolerated and appeared superior to 10 x 3.0 Gy.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI AG-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/cancers16061149-
dc.relation.ispartofCancers, 2024, vol. 16, issue. 6, p. 1149-
dc.relation.urihttps://doi.org/10.3390/cancers16061149-
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.titleRadiotherapy for Metastatic Epidural Spinal Cord Compression with Increased Doses: Final Results of the RAMSES-01 Trial-
dc.typeinfo:eu-repo/semantics/article-
dc.date.updated2024-06-13T10:18:03Z-
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccess-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
cancers-16-01149-v2.pdf1.34 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.